ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS, criado em 2005 (os Estados Unidos de América), a 496 marcas irmãs e 17478 marcas concorrentes. A marca ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS é propriedade de BRISTOL-MYERS SQUIBB COMPANY, uma empresa listada em New York. O setor de ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS é Fabricantes de medicamentos.